MEDFORD, Mass., June 29, 2018 /PRNewswire/ -- INVO Bioscience, Inc. (IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced today that its stock has commenced trading on the OTCQB Market ("OTCQB") after successfully uplisting from the OTC Pink Market.
As a verified market with efficient access to U.S. investors, the OTCQB helps companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation. Multiple reporting standards also give OTCQB companies the flexibility to control reporting costs and complexity, while still providing investors with a premium market for their securities.
The OTCQB is recognized by the SEC as an established public market. Their platform enables companies to provide current public information that investors need to analyze, value and trade a security. Greater visibility is also found through a large network of data distributors and media partners which ensures that trade data, news and disclosures are available to broker-dealers, market data providers, and investors.
The OTCQB platform also offers better trading since investors get an exchange-comparable experience with convenient trading through their preferred broker or financial advisor who normally require a minimum QB status, transparent pricing with real-time quotes, and trusted transparency.
Katie Karloff, CEO of INVO Bioscience commented, "The last year has seen a number of important milestones for INVO Bioscience as we further our mission to increase access to care and expand fertility treatment across the globe through our proprietary INVOcell device and procedure. Today's announcement of our uplisting to the OTCQB is another important step for us which helps to expands the audience of investors that can invest in the Company. We are dedicated to taking the necessary steps to drive value for our shareholders."
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology ("ART"). The INVOcell is the first Intravaginal Culture ("IVC") system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization ("IVF") and Intrauterine Insemination ("IUI"). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504
View original content with multimedia:http://www.prnewswire.com/news-releases/invo-bioscience-announces-uplisting-to-otcqb-market-300674645.html